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Objective: Ideally, cartilage regenerative cell therapy should produce a tissue which closely matches the
microstructure of native cartilage. Benchmark reference information is necessary to assess the quality of
engineered cartilage. Our goal was to examine the variation in glycosaminoglycans (GAGs) in cartilage
zones within human knee joints of different ages.
Design: Osteochondral biopsies were removed from the medial femoral condyles of deceased persons
aged 20e50 years. Fluorophore-Assisted Carbohydrate Electrophoresis (FACE) was used to proﬁle GAGs
through the superﬁcial, middle and deep zones of the articular cartilage. Differences were identiﬁed by
statistical analysis.
Results: Cartilage from the younger biopsies had 4-fold more hyaluronan in the middle zone than
cartilage from the older biopsies. The proportion of hyaluronan decreased with increasing age. Cartilage
from the middle and deep zones of younger biopsies had signiﬁcantly more chondroitin sulphate and
keratan sulphate than the cartilage from older biopsies. This would suggest that chondrocytes synthesise
more sulphated GAGs when deeper in the tissue and therefore in conditions of hypoxia. With increasing
age, there was signiﬁcantly more chondroitin-6 sulphate than chondroitin-4 sulphate. For the ﬁrst time,
unsulphated chondroitin was detected in the superﬁcial zone.
Conclusions: As an outcome measure, FACE offers the potential of a complete, detailed assessment of all
GAGs and offers more information that the widely used 1,9-dimethylmethylene blue (DMMB) dye assay.
FACE could be very useful in the evolving cartilage regeneration ﬁeld.
Crown Copyright © 2015 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. All rights reserved.Introduction
Adult articular cartilage is a complex anisotropic tissue with a
limited capacity for self-repair. Cartilage regenerative cell therapy
was ﬁrst introduced to treat isolated defects of articular cartilage1
which if left untreated are likely to progress to osteoarthritis2.
The cell therapy ﬁeld has continued to evolve and now there is
hope of providing long term beneﬁt to individuals with more
extensive damage and even osteoarthritis3. The ultimate goal of cellto: N.J. Kuiper, Institute for
ty of Keele, The Robert Jones
Research Centre, Oswestry,
er), as3182@cumc.columbia.
evier Ltd on behalf of Osteoarthrit
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ring strategies, Osteoarthritistherapy is to create tissue which closely mimics the microstructure
found in native articular cartilage. If we are to make meaningful
assessments of cartilage generated through cell therapy then the
ﬁeld needs detailed benchmarks concerning the extracellular ma-
trix (ECM) components of native articular cartilage.
The ECM is organised into distinct zones; superﬁcial, middle and
deep4,5. As a result of differences in chondrocyte activity and me-
chanical loading, the ECM composition and its structure varies
greatly between each zone6. In brief, collagen ﬁbres in the super-
ﬁcial zone are densely packed and oriented parallel to the articular
surface, in the middle zone they have a random orientation and in
the deep zone they are oriented perpendicularly to the surface.
Proteoglycan concentration is greatest in the middle zone. Pro-
teoglycans and glycosaminoglycans (GAGs) are critical to the
function of articular cartilage7,8. With the exception of hyaluronan
(HA), GAGs are synthesised covalently bound to core proteins tois Research Society International. All rights reserved.
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endow cartilage with its resistance to compressive loading by
binding and organising water molecules4. Both the proteoglycan
core proteins and their associated GAGs have important functional
roles in tissue remodelling10, up-take of proteins11, intracellular
signalling12 and cell migration13. These functions depend largely on
their post-translational modiﬁcations and the protein cores to
which they are attached. To date, the size and distribution of the
proteoglycans have been well studied in whole tissue7. However
there is a paucity of information detailing the GAGs and even less
information about their variation through full-depth human artic-
ular cartilage. Stockwell and Scott14 were the ﬁrst to use a combi-
nation of histochemical and biochemical methods to show that
GAG concentration varied through the full-depth human articular
cartilage. Since then several investigators have conﬁrmed their
results using immunological and biochemical approaches in a
range of different species15e18. There are excellent immunological
approaches to study GAG distribution in tissue samples15 but these
approaches have a more limited use in the characterisation and
quantitation of GAGs. Most biochemical GAG assays require large
amounts of tissue or cells and do not differentiate between GAG
types16,17. For example, the widely used 1,9-dimethylmethylene
blue (DMMB) dye assay18, is sensitive to 1 mg of total sulphated
GAG but it cannot differentiate GAGs nor detect unsulphated HA.
There are more sensitive and discriminatory approaches such as
ﬂuorophore-assisted carbohydrate electrophoresis (FACE)19e22.
FACE can discriminate between GAGs in small extracts of tissue or
cells19,20, for example in our laboratory, we have used FACE to
analyse GAG proﬁles in as little as 5 mg of cartilage21 or around
25,000e50,000 freshly isolated chondrocytes or chondrons22. As
an outcome measure, FACE offers the potential of a complete,
detailed assessment of GAGs which could be very useful in the
evolving cartilage regenerative cell therapy ﬁeld.
There are three classes of GAGs in cartilage; hyaluronan (HA),
chondroitin sulphate (CS) and keratan sulphate (KS). HA accounts
for 1e10% of GAGs in articular cartilage and is composed of GlcA
and GlcNAc linked by a b1,3-glycosidic bond. Previously, using full-
depth cartilage, we have shown that HA content decreases with
increasing age21. Other published studies using full-depth human
cartilage demonstrated that with increasing age, the molecular
mass of HA decreased but there was a slight increase in HA con-
centration23,24. To date, there are no reports on the absolute
quantities of HA within the superﬁcial, middle and deep zones of
aging cartilage. Almost 80% of GAGs in adult articular cartilage are
CS chains. They are composed of glucuronic acid (GlcA) and N-
acetylgalactosamine (GalNAc). Each monosaccharide may be left
unsulphated, sulphated once, or sulphated twice. As a function of
age, there is increased sulphation at the C6 sites relative to the C4
sites16,21. The monosaccharides are linked by a b1,3 glycosidic bond
and the chain can be terminated with either GalNAc4S (in which S
stands for sulphate), GalNAc6S or GalNAc4,6S21,25. It is still not clear
why there is such variation in the terminal sugar. KS chains
represent 5e20% of the GAGs in articular cartilage. KS is composed
of galactose (Gal) and N-acetylglucosamine (GlcNAc) linked by a
b1,4 glycosidic bond26,27. KS can be branched. KS chains can be
modiﬁed by O-sulphation of the hydroxyl groups at C6 of both the
Gal and/or the GlcNAc, resulting in unsulphated, monosulphated or
disulphated repeat disaccharides. KS chains demonstrate an age-
related increase in chain length and sulphation, and the amount
of KS has been shown to increase progressively through the full-
depth of cartilage7.
A small number of studies have assessed differences in chon-
drocyte phenotype5, matrix morphology6 and compressive prop-
erties28 through the full-depth of articular cartilage. To date there
are only a small number of reports describing GAG variationPlease cite this article in press as: Kuiper NJ, Sharma A, A detailed quan
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age7,16,17,23,29. Most of these studies do not report absolute HA, CS or
KS concentrations. Most cartilage regeneration strategies are
focussed on “one size ﬁts all” which does not take into account the
potential variations within the cartilage microanatomy. A tissue
engineered construct might be suitable for implantation into a 30
year olds knee but not necessarily a 50 year old knee. With a view
towards this we have utilised the well-known technique of
FACE19e22 to proﬁle GAGs in articular cartilage obtained from a
well-deﬁned site in the adult knee joint. The overall goal was to
quantify and compare both the distribution and the absolute con-
centrations of HA, CS and HA in articular cartilage obtained from
the medial femoral condyles in an age-range of macroscopically
normal adult human knees. Comparisons were made through the
full-depth of the tissue. Our intention is that the information ob-
tained will provide a valuable benchmark for cartilage regenerative
strategies. Further, that FACE becomes an additional outcome
measure to support existing immunological and DMMB assay data.
Materials and methods
Biopsies of cadaveric human knees
Four cadaveric knees (22, 30, 40 & 50 years old) were obtained
within 24 h of death from the UK Human Tissue Bankwith approval
by the Trent Research Ethics Committee, UK. Subjects were victims
of road accidents and had not suffered with acute or chronic dis-
ease. All knee joints appeared healthy and intact apart from the 50-
year old whose articular cartilage showed slight surface ﬁbrillation.
From each joint, nine osteochondral biopsies (1.8 mm in diameter,
~5 mm in height) were taken perpendicularly from the articulating
surface through the full depth of cartilage and subchondral bone of
the medial femoral condyles.
Treatment of biopsies
One unﬁxed biopsy was directly sectioned at 5 mm with a con-
ventional ultramicrotome and a glass knife. Under a dissection
microscope, the thickness of hyaline articular cartilage from the
articular surface to the cartilageebone interface was measured and
used to deﬁne three zones: superﬁcial (~10% of thickness), middle
(~10%), and deep (~80%). The subchondral bone from the remaining
eight biopsies was carefully removed after scoring along the car-
tilageebone interface. The articular cartilage was further divided
into the superﬁcial, middle, and deep zones with a scalpel under a
dissection microscope. Each piece of tissue was snap frozen in
liquid nitrogen-cooled hexane and stored in liquid nitrogen until
studied.
Preparation of GAG saccharides for FACE
GAGs were ethanol extracted from each portion of biopsy using
our previously published methodology21,22. Puriﬁed GAG chains
were cleaved using GAG-speciﬁc enzymes (Seikagaku). Brieﬂy, HA
was digested into disaccharides (DDiHA) using 100 mU/ml of hy-
aluronidase Streptococcus dysgalactiae for 1 h at 37C21. CS was
digested into disaccharides (6-sulphated, DDi6S; 4-sulphated,
DDi4S; and unsulphated, DDi0S) with 100mU/ml of chondroitinase
ABC (cABC) for 3 h at 37C. Sulphation of CS was conﬁrmed by in-
cubation of cABC-digested samples with 100 mU/ml of
chondroitin-4ase and/or chondroitin-6ase for 12 h at 37C. The
non-reducing terminal sugars of CS were identiﬁed bymercuric ion
treatment. KS was digested as previously described19e22. KS
digestion was assessed by sequential digestion with 100 mU/ml of
keratanase II for 3 h and 100 mU/ml of endo-b-galactosidase fortitative outcome measure of glycosaminoglycans in human articular
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14 h and 100 mU/ml of keratanase II for 3 h. This approach will
generate ﬁve digestion products from the internal KS chain
(unsulphated disaccharide, GlcNAcb1,3Gal; monosulphated disac-
charide GlcNAc6Sb1,3Gal; fucosylated trisaccharide, Galb1,2
[fuca1,3]GlcNAc6S; monosulphated disaccharide, Galb1,4Glc-
NAc6S; disulphated disaccharide, Gal6Sb1,4glcNAc6S) and one
digestion product which caps the KS chain (disulphated trisac-
charide NeuAa2,3Gal6Sb1,4GlcNAc6S).
Fluorotagging of cleaved GAGs for separation on FACE gels
Lyophilised enzyme-digested cleaved GAG samples and pre-
deﬁned saccharide standards (Seikagaku) were reconstituted with
the ﬂuorescent tag, 5 ml 12.5 mM 2-aminoacridone, in glacial acetic
acid/DMSO (3:17, v/v) and incubated at room temperature for
15 min. Five microlitres of 1.25 M sodium cyanoborohydride in
distilled deionised water were added. Samples were incubated at
37C for 16 h. After tagging, 10 ml of 25% glycerol were used to
quench excess sodium cyanoborohydride. Electrophoresis on
monosaccharide FACE gels was carried out for 80 min at 4C.
FACE gel imaging & quantitation of GAGs
Gels were placed on a transilluminator light box ﬁtted with a
312 nm light source. Fluorescent images were captured using a
GelDoc-It High CCD Camera (12-bit depth, UVP, Cambridge, UK) and
the mean pixel density for each product band was quantiﬁed using
LabWorks Software (UVP). For each gel, FACE product bands were
identiﬁed by their co-electrophoresis with a range of pre-deﬁned
saccharide ﬂuorotagged standards. Two image exposures were
captured. The ﬁrst exposure was used for quantitation as it had all
of the pixels within a linear 12-bit depth range to provide base line
data and the second exposure over-saturated pixel intensity to
allow identiﬁcation of less abundant structures. Accurate quanti-
tation was achieved between 10 and 400 pmole of product. Quality
control was rigorously and routinely performed using a mixture of
a known concentration of ﬂuorotagged saccharide standards and
enzyme-digested appropriate substrate controls. To control for gel-Fig. 1. A representative FACE gel of hyaluronidase and chondroitinase digestion products obt
biopsy (Lanes C & D). The ﬁrst exposure (1A) was used for quantitation to provide baseline d
of less abundant structures. Lanes A and F contain a mixture of pre-deﬁned ﬂuorotagged
chondroitin disaccharides (DDiOS), (3) N-acetyl galactosamine-6 sulphate (6S-galNAc), (4)
amine (4,5S-galNAc). Lane F: (6) hyaluronan disaccharides (DDiHA), (7) chondroitin 6-sulp
matan sulphate disaccharides (DDi2S), (10/11) DDi4,6S, (12/13) DDi2,6S. Cadaveric biop
chondroitinase ABC (Lane D & E) chondroitinase ABC. The migratory positions of (6) DDiH
Please cite this article in press as: Kuiper NJ, Sharma A, A detailed quan
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multiple gels.
Statistical analysis
Results for the eight biopsies are expressed as the mean con-
centration (g/L) and their 95% conﬁdence intervals (CI). Two-way
analysis of variance (ANOVA), followed by a Tukey-Honest Signiﬁ-
cant Difference (HSD) post hoc test was performed to determine
zone and age dependent differences in GAG content. For all ana-
lyses a p-value below 0.05 was assumed to denote statistical sig-
niﬁcance. All statistical analyses were performed using GraphPad
Prism 6 (GraphPad Software Inc., San Diego, USA).
Results
FACE analysis of hyaluronidase and chondroitinase digestion
products
Figure 1 is a representative FACE gel showing the co-
electrophoresis of a known concentration of monosaccharide and
disaccharide ﬂuorotagged standards alongside hyaluronidase and
chondroitinase digestion products isolated from a 30 year old
(n ¼ 8) and a 40 year old (n ¼ 8). GAG-speciﬁc enzymes were used
at a concentration and a time which is known to completely
depolymerise the HA and CS21,22. Digital images for each gel were
taken at two exposures. The image in Fig. 1A has all pixels within a
12-bit depth range and was used for quantiﬁcation. The image in
Fig. 1B has oversaturated pixel intensity and was used to identify
any less abundant structures. All cartilage samples contained HA
disaccharides (DDiHA) and CS disaccharides (DDi0S, DDi4S and
DDi6S). No other disaccharide bands were observed. Data to
conﬁrm the terminal sugars and sulphation of the CS and are not
shown.
Hyaluronan (HA) disaccharide analysis
The quantities of total HA disaccharides (DDiHA) in each zone
are shown in Fig. 2. HAwas detected in all cartilage zones and in allained from the superﬁcial zones of a 30 year old biopsy (Lanes B & E) and a 40 year old
ata. The second exposure (1B) had over-saturated pixel intensity to allow identiﬁcation
saccharide standards. Lane A: (1) N-acetyl galactosamine (galNAc), (2) unsulphated
N-acetyl galactosamine-4 sulphate (4S-galNAc), and 4-/6-sulphated N-acetyl galactos-
hate disaccharides (DDi6S), (8) chondroitin 4-sulphate disaccharides (DDi4S), (9) der-
sies were digested with hyaluronidase Streptococcus dysgalactiae SD (Lane B & C),
A, (2) DDiOS, (7) DDi6S and (8) DDi4S are also shown.
titative outcome measure of glycosaminoglycans in human articular
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Fig. 2. Hyaluronan (HA) disaccharide concentration (g/L) within the superﬁcial, middle
and deep zones of an age range (22, 30, 40 & 50 years) of human articular cartilage
biopsies. The graph illustrates the mean concentration (g/L) ± 95% conﬁdence limits
(CL) for the eight biopsies. Zones with signiﬁcantly different HA content when
compared between ages are indicated by arrows on the associated horizontal bars.
N.J. Kuiper, A. Sharma / Osteoarthritis and Cartilage xxx (2015) 1e94ages. The cartilage biopsies (n ¼ 8) from the 22 year old had the
highest amount of HA (full-depth mean 0.371, 95% CI 0.273,0.483 g/
L) whilst the cartilage biopsies (n ¼ 8) from the 50 year old had the
lowest amount of HA (full-depth mean 0.031, 95% CI 0.026,0.039 g/
L). Overall, the mean concentration of HAwas highest in the middle
zone of the cartilage biopsies. The mean concentration of HA was
signiﬁcantly higher in the middle and deep zones of the cartilage
biopsies obtained from the 22 year old compared with the 40 year
old. Within all cartilage zones the concentration of HA content
decreased with age.Chondroitin sulphate (CS) disaccharide analysis
The quantities of total CS disaccharides (DDi0S, DDi4S and
DDi6S) in each zone are shown in Fig. 3A. For the 22 and 30 yearPlease cite this article in press as: Kuiper NJ, Sharma A, A detailed quan
cartilage for cell therapy and tissue engineering strategies, Osteoarthritisolds, the mean concentration of CS was signiﬁcantly higher in the
middle and deep zones of the cartilage compared with the super-
ﬁcial zone (22 year old; middle zone p¼ 0.027, deep zone p¼ 0.001
& 30 year old; middle zone p¼ 0.001, deep zone p¼ 0.008). Overall
total CS concentration (g/L) decreased with increasing age. Table I
illustrates the distribution of DDi0S%, DDi4S% and DDi6S% across
the zones and ages. DDi0S decreased with age, with little or no
DDi0S detected in the 40 and 50 year old subjects. As shown in
Fig. 3B, DDi6S% increased and DDi4S% decreased with increasing
age. There was signiﬁcantly more DDi6S than DDi4S in the middle
zone and deep zones for all tissue ages.
Identiﬁcation of non-reducing terminal structures on CS
We were able to identify two non-reducing terminal sugars;
GalNAc4S and GalNAc6S. Table II shows the total mean concen-
tration (g/L) of GalNAc4S and GalNAc6S for each biopsy. The chain
terminal residues of adult cartilage CS clearly change with age. CS
chains from the 22 and 30 year old biopsies had more GalNAc6S
than GalNAc4S non-reducing termini. CS chains from the 40 and 50
year old biopsies had less GalNAc6S in comparison to the 22 and 30
year old biopsies. Statistical analysis using Tukey-Honest HSD
conﬁrmed that there was signiﬁcantly more GalNA6S than Gal-
NAc4S in the deep zone in all ages (22 years p ¼ 0.002, 30 years
p ¼ 0.001, 40 years p ¼ 0.002 and 50 years p ¼ 0.008).
Proportion of KS in the biopsies
The quantities of total KS saccharides in each zone are shown in
Fig. 4. The superﬁcial zone contained very little KS whilst, for all
ages, KS content was highest in the deep zone. The mean concen-
trations (g/L) of all KS digestion products detected by FACE are
shown in Table III. KS digestion generated one digestion product
which caps the KS chain (disulphated trisaccharide Neu-
Aa2,3Galb1,4GlcNAc6S) and ﬁve digestion products from the in-
ternal KS chain (unsulphated disaccharide, GlcNAcb1,3Gal;
monosulphated disaccharide GlcNAc6Sb1,3Gal; fucosylated trisac-
charide, Galb1,2[fuca1,3]GlcNAc6S; monosulphated disaccharide,
Galb1,4GlcNAc6S; disulphated disaccharide, Gal6Sb1,4glcNAc6S).
The monosulphated disaccharide, Galb1,4GlcNAc6S and the dis-
ulphated disaccharide, Gal6Sb1,4glcNAc6S were present through
the full-depth at all ages. Gal6Sb1,4GlcNAc6S made up the majority
of the internal KS chains in all ages. Galb1,2[fuca1,3]GlcNAc6S was
absent in the 22 and 30 year old biopsies but appeared in the 40 and
50 year old biopsies. Whilst GlcNAcb1,3Gal was present in the 22
and 30 year old biopsies but absent in the 40 and 50 year old
biopsies.
Comparison of the proportions of CS, HA and KS in the biopsies
FACE analysis revealed the differences in the proportions of HA,
CS and KS through full-depth cartilage at all ages. These data are
summarised in Fig. 5 where each GAG, with its constituent
saccharide component, is expressed as a total percentage of GAGs
analysed. HA comprised no more that 6% of the total GAGs and was
predominantly present in themiddle zone of the 22, 30 and 40 year
old biopsies. There is a greater proportion of KS to CS in all but the
superﬁcial zone of the 40 and 50 year old biopsies.
Discussion
In this study we have focussed on GAGs and their distribution
within cartilage since a detailed understanding of native articular
cartilage microstructure could provide essential reference points
for the evaluation of cartilage cell therapies. This study provides atitative outcome measure of glycosaminoglycans in human articular
and Cartilage (2015), http://dx.doi.org/10.1016/j.joca.2015.07.011
Fig. 3. Total chondroitin disaccharides (CS; DDi0S, DDi4S and DDi6S) concentration (g/L) (Figure 3A) and the concentration of chondroitin DDi4S and DDi6S saccharides (Figure 3B)
within the superﬁcial, middle and deep zones of an age range (22, 30, 40 & 50 years) of human articular cartilage biopsies. The graph the mean concentration (g/L) ± 95% conﬁdence
limits (CL) for the eight biopsies. Zones with signiﬁcantly different CS disaccharide content when compared with those ages are indicated by arrows on the associated horizontal
bars.
N.J. Kuiper, A. Sharma / Osteoarthritis and Cartilage xxx (2015) 1e9 5powerful, detailed analysis of the variation in GAG saccharides from
an age range of cadaveric articular cartilage and to our knowledge
there is no other study available providing such insights. One
drawback to our study is that FACE only generates mono- and di-
saccharides data, and these are difﬁcult to correlate with total
cartilage GAG molecules. Another drawback is that we have only
sampled one knee joint for each decade (20 yearse50 years) and
that we should be cautious in how we interpret these data. Despite
these two drawbacks, we demonstrate three key points. First, age
and zone are important determinants of GAG variation and content.
Overall, this is not surprising since many studies have reportedTable I
The calculated data for all chondroitin saccharide structures (DDi0S, DDi4S and DDi6S),
proportion of each saccharide within the superﬁcial, middle and deep zones. Data are sh
Chondroitin saccharide structures Percentage (%)
Age (years) 22 30
Zone Superﬁcial Middle Deep Superﬁcial M
DDi0S 68 28 18 27 1
DDi4S 10 12 20 21
DDi6S 22 60 62 52 7
Please cite this article in press as: Kuiper NJ, Sharma A, A detailed quan
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cell size, and ECM gene expression4e7,23,24. What is of interest is
that this detailed understanding of GAGs, on the whole, is not
translated into strategies for the regeneration of articular cartilage.
Second, the detailed analysis of full-depth cartilage has revealed
subtle variations in GAG content and compositionwhich would not
be identiﬁed by thewidely used DMMB assay18. It has recently been
reported that the DMMB assay can result in an overestimation of
sulphated GAGs because of interference from HA and nucleic
acids30. Thirdly, very little cartilage is required for a complete GAG
analysis which is an important consideration.as detected by FACE analysis. Data are represented as a percentage to illustrate the
own for each subject aged 22, 30, 40 & 50 years old
40 50
iddle Deep Superﬁcial Middle Deep Superﬁcial Middle Deep
8 17 0 1 1 0 0 3
9 15 98 3 1 2 3 0
3 68 2 96 98 98 97 97
titative outcome measure of glycosaminoglycans in human articular
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Please cite this article in press as: Kuiper NJ, Sharma A, A detailed quan
cartilage for cell therapy and tissue engineering strategies, OsteoarthritisWe have shown that HA levels decrease with increasing age and
that the middle zone is relatively HA-rich. Our ﬁndings agree with
previous studies using more laborious and time consuming
biochemical approaches and large tissue samples23,24,29. For
example one previous study29 reported similar results using a
biotinylated hyaluronic acid binding region probe to assess the
distribution of HA in full-depth cartilage from subjects aged 19, 30
and 37 years. In cartilage, HA binds and immobilises aggrecan to
form massive aggregates with ﬁxed negative charges that retain
water and endow the tissue with its critical mechanical properties.
Ideally cell based therapies and tissue engineered constructs would
need to reach the same or greater concentration of HA within age-
matched tissue to match the maturity of native cartilage. Some
recent studies have begun to take this into consideration31e33. For
example, one study33 used composition-based ﬁnite element
modelling to demonstrate that by ﬁne tuning the temporal depo-
sition of GAGs they could inﬂuence the swelling behaviour and the
resultant compressive stiffness of tissue engineered cartilage. Our
ﬁndings might provide further insights to help achieve an ideal
maturation state that is compatible with cartilage integration.
In previous studies, including our own, changes in CS sulphation
levels and patterns have been associated with mechanical loading,
aging, type of scaffold and chondrocyte metabolic activ-
ity6,16,17,22,33,34. Using capillary electrophoresis, Bayliss et al.16
showed that from age 20 onwards both DDi6S and DDi4S levels
were relatively constant but their distributionwithin different knee
cartilage zones changed with increasing age. The same study also
found that DDi0S was constant throughout life. Using the DMMB
assay, Rogers et al.17 showed reported higher weight bearing re-
gions of knee cartilage had higher concentrations of sulphated
GAGs but they did not assess changes in depth. By contrast to these
two studies, we report absolute levels for all CS saccharides within
each zone. We found that DDi6S% increased and DDi4S% decreased
with increasing age, and that there were clear differences within
the cartilage zones. The functional implication of increased CS-6 in
adult native cartilage might be linked to the integrity of the artic-
ular cartilage. One could speculate that at implantation it would be
better to have the deep andmiddle zones of the tissuewith a higher
ratio of CS-6 to CS-4 so that it could immediately match the
swelling pressures and cope with variable compressive loads. We
found DDi0S to be at its highest in the superﬁcial zone in the 22 and
30 year old biopsies and the levels decreased in the older biopsies.
The presence ofDDi0Swithin the superﬁcial zone is a novel ﬁnding.
This ﬁnding could suggest that there is less 4,6-sulfotransferase
activity to produce less or no sulphated CS to reduce swelling
pressure within the superﬁcial zone. Alternatively there could be
different types of proteoglycans within the superﬁcial zone. This
result suggests that it would be ideal to implant a tissue with less
sulphated GAG in the superﬁcial zone.
Plaas et al.25 were the ﬁrst to characterise the non-reducing
termini on CS in cartilage tissue. Using high performance liquid
chromatography, they determined that the predominant terminal
structures were the monosaccharides; GalNAc4S and GalNAc4,6S.
Theywere not able to quantitate GalNAc6S in their study since it co-
eluted with another product. Further work by Calabro et al.35 using
FACE identiﬁed GalNA4S, GalNAc6S and GalNAc4,6S as non-
reducing terminal structures on CS. The internal sulphation
pattern of the CS chain is thought to be independently regulated
from the rest of the CS chain such as the terminal non-reducing
sugar34,36. The relevance of the different non-reducing terminal
sugar residues of CS chains is still not clear but it could explain how
CS chain elongation is controlled36. We were able to identify two
non-reducing terminal sugars; GalNAc4S and GalNAc6S. We did not
detect GalNAc4,6S in any of our subjects possibly because levels
were too low for detection by FACE or that the terminal saccharidetitative outcome measure of glycosaminoglycans in human articular
and Cartilage (2015), http://dx.doi.org/10.1016/j.joca.2015.07.011
Fig. 4. The concentration of keratan sulphate (KS) saccharides (g/L) within the su-
perﬁcial, middle and deep zones of an age range (22, 30, 40 & 50 years) of human
articular cartilage biopsies. The graph illustrates the mean concentration (g/L) ± 95%
conﬁdence limits (CL) for the eight biopsies. Zones with signiﬁcantly different KS
saccharide content when compared with those ages are indicated by arrows on the
associated horizontal bars.
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N.J. Kuiper, A. Sharma / Osteoarthritis and Cartilage xxx (2015) 1e9 7had already been catabolically removed into the synovial ﬂuid. To
our knowledge there have been no studies to investigate the
functional implications of the different terminal structures on CS
chains in cartilage.
KS, like CS, is an important component of aggrecan and
together they provide cartilage with its resistance to physical
stress and load27. The KS digestion products identiﬁed in our study
concurred with previously published studies employing FACE19,37.
The relative proportion of KS increased progressively through the
depth of cartilagewith increasing age. Using endo-b-galactosidase
allows the identiﬁcation of products from unsulphated regions of
KS21,22,37. It was interesting to ﬁnd unsulphated disaccharidePlease cite this article in press as: Kuiper NJ, Sharma A, A detailed quantitative outcome measure of glycosaminoglycans in human articular
cartilage for cell therapy and tissue engineering strategies, Osteoarthritis and Cartilage (2015), http://dx.doi.org/10.1016/j.joca.2015.07.011
Fig. 5. The differences in the proportions of KS, HA and CS within the superﬁcial, middle and deep zones of human cartilage biopsies from A: 22 year old, B: 30 year old, C: 40 year
old and D: 50 year old. Each mean GAG concentration (g/L) for the eight biopsies, with its constituent disaccharide and monosaccharide components, is expressed as a total
percentage of GAGs analysed by FACE.
N.J. Kuiper, A. Sharma / Osteoarthritis and Cartilage xxx (2015) 1e98(GlcNAcb1,3Gal) in the 22 and 30 year old biopsies but not in the 40
and 50 year old biopsies. The sulphation levels of KS increased from
around 50e80% with advancing age. For the more heavily sulph-
ated KS, there appeared to be an inverse relationship between
tissue depth and KS content. This would suggest that chondrocytes
synthesise more sulphated GAGs when in conditions of hypoxia.
One could speculate that in the middle and deep zones, the sul-
phation patterns of the KS components on proteoglycans inﬂuence
their aggregation and dissociation.
All of our data largely agree with the previously published work
by Elliott & Gardner24 who assessed surface and deep cartilage by
cellulose acetate electrophoresis. The use of the powerful and
sensitive approach of FACE has enabled us to further build upon
their work to provide detailed analysis of HA, CS and KS. From our
study, we believe that we have shown that the absolute concen-
trations of GAG are just as important as their distribution. We are
already using FACE to fully characterise native cartilage and tissue
generated through cartilage regenerative cell therapy approaches.
Ideally we could use FACE in combination with existing immuno-
logical methods as another useful outcome measure.Contributions
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